Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial
CRUK Lung Cancer Centre of Excellence · University College London · +16 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
1,441
total citations
- FWCI
- 74.58
- Percentile
- 100%
- References
- 24
Citations per year
Authors
18- JAJonathan A. LedermannCorresponding
CRUK Lung Cancer Centre of Excellence, University College London
- PHPhilipp Harter
Kliniken Essen-Mitte, University of Duisburg-Essen
- CGCharlie Gourley
MRC Institute of Genetics and Molecular Medicine, Edinburgh Cancer Research
- MFMichael Friedländer
UNSW Sydney
- IVIgnace Vergote
KU Leuven
Topics & keywords
Topics
Keywords
- Olaparib
- Medicine
- BRCA mutation
- Oncology
- Internal medicine
- Regimen
- Ovarian cancer
- Placebo
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.